AdaptHealth (AHCO) EBITDA (2018 - 2026)

AdaptHealth has reported EBITDA for 9 years, with the latest figure at -$25.0 million in Q2 2026.

• On a quarterly basis, EBITDA fell 116.61% year-over-year to -$25.0 million in Q2 2026; TTM through Jun 2026 was $255.6 million, a 56.98% decrease from a year earlier, with the FY2025 full-year figure at $452.5 million, down 25.44% from the prior year.
• EBITDA was -$25.0 million for Q2 2026 at AdaptHealth, down from $107.1 million in the prior quarter.
• The five-year high for EBITDA was $182.7 million in Q4 2024, with the low at -$370.7 million in Q3 2023.
• Average EBITDA over 5 years is $76.6 million, with a median of $123.8 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA sank 373.91% in 2023, then jumped 239.44% in 2024.
• Over 5 years, EBITDA stood at $119.0 million in 2022, then slumped by 210.06% to -$131.0 million in 2023, then surged by 239.44% to $182.7 million in 2024, then plunged by 89.48% to $19.2 million in 2025, then slumped by 230.08% to -$25.0 million in 2026.
• The last three EBITDA figures came in at -$25.0 million (Q2 2026), $107.1 million (Q1 2026), and $19.2 million (Q4 2025), per Business Quant data.